Shanghai INT Medical Instruments Co Documente
Documente
0
Ticker
1501.HK
ISIN
CNE100003NH7
Shanghai INT Medical Instruments Co SEC Filings
Tip | Raport | Dată |
|---|---|---|
| Nu sunt disponibile documente | ||
Shanghai INT Medical Instruments Co Documente 2026
Această pagină conține toate documentele oficiale și depunerile SEC pentru acțiunea Shanghai INT Medical Instruments Co (1501.HK, ISIN: CNE100003NH7). Aceasta include rapoarte anuale (Form 10-K), rapoarte trimestriale (Form 10-Q) și tranzacții interne (Form 4). În prezent sunt disponibile 0 documente. Datele sunt actualizate regulat pentru a oferi investitorilor o prezentare generală completă a depunerilor de reglementare ale Shanghai INT Medical Instruments Co.
Shanghai INT Medical Instruments Co Analiza acțiunilor
Shanghai INT Medical Instruments Co Shanghai Kindly Medical Instruments Co., Ltd. generates revenue through the research and development, manufacturing, and sales of interventional and implantable medical devices. The company's cardiovascular intervention business focuses on cardiovascular interventional medical devices, related molds, and accessories, with main products including inflation device, Introducer set, and guidewire. It serves domestic and overseas markets such as Europe and the United States, targeting healthcare providers and medical institutions that require specialized equipment for minimally invasive procedures. The firm expands its product portfolio beyond cardiovascular devices to include neurological interventional medical devices and endocardia implantable medical devices, catering to diverse clinical needs. Its domestic market presence is complemented by exports to Europe and the United States, where it supplies hospitals and clinics seeking high-quality medical devices for patient care. The company's full-time workforce of 1,532 employees supports these operations, ensuring consistent production and delivery of its medical device solutions. Shanghai Kindly Medical Instruments Co., Ltd. operates with a clear focus on interventional and implantable medical devices, leveraging its R&D capabilities to develop specialized products. Its business model relies on direct sales of these devices to healthcare facilities, with no mention of third-party partnerships or additional revenue streams beyond the core product lines described.